



ANNOUNCEMENT

1 February 2011, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that following the Company's achievement of four quarters of positive net operating cash flows, the Company will not be required to submit any further Appendix 4C quarterly cash flow reports in accordance with the ASX Listing Rules.

-ENDS-

For further information contact:

Dr Roger Aston 0402 762 204

Lisa Pendlebury 0419 548 434, l.pendlebury@halcygen.com

Mayne Pharma Profile:

Mayne Pharma Group Limited (Mayne Pharma) is an Australian specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs.

Mayne Pharma has a long and successful history of developing and commercializing improved pharmaceuticals and has launched and marketed numerous products through partnerships with licensees in various countries around the world. Mayne Pharma focuses on delivering to patients improved versions of existing drugs in order to advance safety, efficacy or ease of administration.

A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, USA, Europe and Asia and a manufacturing facility based in Salisbury, South Australia that employs over 150 people on a 32 acre site. The facility also undertakes the manufacture of products under contract for third parties to TGA, FDA and EU regulatory guidelines.